Abstract

Imatinib is a BCR-ABL tyrosine kinase inhibitor used for the treatment of a variety of diseases including Philadelphia chromosome positive (Ph+) leukemia. We report a 15 year old male patient presenting with symptomatic acute intracerebral hemorrhage (ICH) in midbrain while on imatinib more than three years after completion of therapy for Ph + B-ALL. The patient denied recent trauma history and consumption of other medication. Laboratory findings did not show any signs of relapse, coagulopathy nor thrombocytopenia. Under the impression of imatinib related ICH, imatinib was discontinued and with conservative management the patient recovered without neurologic sequalae. This case demonstrates the first pediatric case of spontaneous ICH as a rare complication of imatinib.

摘要

伊马替尼是一种BCR-ABL酪氨酸激酶抑制剂，用于治疗多种疾病，包括费城染色体阳性（Ph +）白血病。我们报告了一名15岁的男性患者，在完成Ph + B-ALL治疗超过三年后，在中脑出现症状性急性脑出血（ICH），而在接受伊马替尼治疗。该患者否认近期有创伤史，也未服用其他药物。实验室检查结果未显示任何复发迹象，凝血病或血小板减少症。在与伊马替尼相关的ICH的印象下，伊马替尼被停药，经过保守治疗，患者康复了，没有神经性角膜溃疡。该病例证明了自发性ICH的首例儿科病例是伊马替尼的罕见并发症。